Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

NCT06350318 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Follicular Lymphoma
Marginal Zone Lymphoma
B-Cell Lymphoma

Interventions

DRUG: Zanubrutinib
DRUG: Rituximab

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]